Project 3 will test the overarching hypothesis that variation in the gene (ADRA2A) encoding the a2A- adrenergic receptor (a2A-AR) is an important determinant of platelet aggregation and insulin secretion in pathological and physiological conditions that occur in the setting of sympathetic activation. Recent independent lines of evidence, including our own studies, implicate a2A-AR genetic variation, particularly haplotype 4 (characterized by rs553668, a variant present in 16-24% of people), as a mediator of important differences in adrenergically-mediated responses. However, the clinical consequences of such variability, which are most likely to be manifest under conditions of sympathetic activation, are not known. Platelet aggregation in response to epinephrine is mediated by a2A-ARs;there is increased aggregation and increased risk of myocardial infarction concurrent with the early morning diurnal peak in sympathetic activity. The contribution of genetic variability to adrenergically-mediated diurnal platelet responses is not known. Accordingly, Specific Aim 1 will test the hypothesis that ADRA2A haplotype affects diurnal platelet aggregation responses. Sympathetic activation, in addition to increasing platelet aggregation, also inhibits insulin secretion;this response is mediated by a2A-ARs and is affected by ADRA2A genetic variation, in particular, haplotype 4. Two conditions characterized by hyperglycemia in the setting of sympathetic activation are stress-induced hyperglycemia, such as commonly occurs in patients with serious illness, and gestational diabetes. Thus, we will test the hypothesis that ADRA2A haplotype is associated with increased risk of stress-induced hyperglycemia in patients with myocardial infarction (Specific Aim 2), and gestational diabetes (Specific Aim 3). The proposed studies will translate basic science findings and previous genetic discovery studies into fundamental mechanistic information that is clinically relevant. This will allow, on the basis of genetic information, the future targeting for interventions those individuals at increased risk of specific adverse outcomes that occur under conditions characterized by increased sympathetic drive.
Sympathetic activation is important in the pathogenesis of many diseases. The ability to identify patients at high risk of complications mediated by increased sympathetic activity would allow the eariy identification of disease and targeted interventions to prevent complications in this group.
|Biaggioni, Italo; Calhoun, David A (2016) Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep. Hypertension 68:1338-1339|
|Harder, RenÃ©; Malow, Beth A; Goodpaster, R Lucas et al. (2016) Heart rate variability during sleep in children with autism spectrum disorder. Clin Auton Res 26:423-432|
|Mar, Philip L; Nwazue, Victor; Black, Bonnie K et al. (2016) Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction. Chest 149:1252-60|
|Shibao, Cyndya A; Celedonio, Jorge E; Ramirez, Claudia E et al. (2016) A Common CD36 Variant Influences Endothelial Function and Response to Treatment with Phosphodiesterase 5 Inhibition. J Clin Endocrinol Metab 101:2751-8|
|Adefurin, Abiodun; Darghosian, Leon; Okafor, Chimalum et al. (2016) Alpha2A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction. Int J Cardiol 215:482-6|
|Raj, Satish R (2016) Row, row, row your way to treating postural tachycardia syndrome. Heart Rhythm 13:951-2|
|Joy, Nino G; Perkins, Jennifer M; Mikeladze, Maia et al. (2016) Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans. J Diabetes Complications 30:1275-81|
|Lateef, Dalya M; Xiao, Cuiying; Brychta, Robert J et al. (2016) Bombesin-like receptor 3 regulates blood pressure and heart rate via a central sympathetic mechanism. Am J Physiol Heart Circ Physiol 310:H891-8|
|Harder, Rene; Diedrich, Andre; Whitfield, Jonathan S et al. (2016) Smart Multi-Frequency Bioelectrical Impedance Spectrometer for BIA and BIVA Applications. IEEE Trans Biomed Circuits Syst 10:912-9|
|Iwuchukwu, Otito F; Ramirez, Andrea H; Shi, Yaping et al. (2016) Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics 26:510-516|
Showing the most recent 10 out of 300 publications